In Vivo Model Development for Endometriosis

Ace Therapeutics offers a comprehensive in vivo Endometriosis model development service designed to accelerate the discovery and evaluation of novel therapies for endometriosis. Leveraging a broad range of validated animal models, our service provides robust, translationally relevant platforms to support preclinical efficacy, mechanism-of-action, and safety studies for academic and industry partners.

Endometriosis is a chronic, estrogen-dependent inflammatory disorder characterized by the ectopic growth of endometrial tissue, leading to pain, infertility, and diminished quality of life. Animal models are indispensable for elucidating disease mechanisms and evaluating potential treatments prior to clinical trials. Ace Therapeutics employs a diverse selection of species, including non-human primates (Callithrix jacchus, Macaca fascicularis, Papio anubis), rodents (Mus musculus, Rattus norvegicus), and various mouse strains (Balb/c, C57BL/6, CB17, CD-1, Wistar, Sprague Dawley). These models recapitulate key features of human endometriosis, such as lesion formation, hormonal responsiveness, immune modulation, and pain behaviors, providing highly relevant systems for translational research.

Surgically-Induced Models

Surgically-induced models involve the transplantation or grafting of endometrial or uterine tissue into ectopic sites within the animal, such as the peritoneal cavity or abdominal wall. This approach is established in both rodents (mice, rats) and non-human primates. The methodology closely mimics the pathogenesis of human endometriosis by allowing tissue to attach, invade, and develop into lesions. Key advantages include reproducibility, control over lesion location and number, and the ability to study both early and chronic disease stages. These models are widely used for evaluating pharmacological interventions, studying lesion biology, and investigating pain and infertility mechanisms.

Chemically-Induced Models

Chemically-induced models utilize hormonal agents, such as estradiol or estradiol benzoate, to stimulate endometriosis-like lesion development, often in conjunction with surgical or grafting techniques. These models are primarily established in rodents and can be combined with ovariectomy to modulate endogenous hormone levels. The primary advantages are ease of induction, scalability, and the ability to model hormone-dependent disease processes. Applications include screening of hormone-modulating therapies, studying the role of endocrine factors, and investigating the impact of environmental exposures on disease progression.

Genetically Engineered and Immunodeficient Models

Genetic and immunodeficient models include knockout or transgenic mice (e.g., Il33, Il2rg, Rag2, Greb1) and severe combined immune deficiency (SCID) strains. These models enable the study of specific gene functions, immune system contributions, and human tissue xenografting. The use of immunodeficient mice allows for the engraftment of human endometrial tissue or cells, creating highly translational models for human disease. Advantages include the ability to dissect molecular pathways, assess immune interactions, and evaluate human-specific therapies, such as biologics or cell-based approaches.

Xenograft and Allograft Models

Xenograft models involve the transplantation of human endometrial tissue or immortalized cells into immunodeficient mice, while allograft models use tissue or cells from genetically distinct animals of the same species. These methods enable the study of human endometriosis pathology in vivo and facilitate the testing of candidate therapeutics in a human tissue context. Advantages include high translational relevance, the ability to use human-specific readouts (e.g., luciferase imaging), and modeling of immune-tumor interactions. Applications include preclinical efficacy testing, biomarker discovery, and personalized medicine research.

Ace Therapeutics delivers a turnkey solution for in vivo endometriosis research, encompassing model selection, custom protocol development, surgical induction or tissue transplantation, and comprehensive endpoint analysis. Key efficacy endpoints include lesion number, size, and histopathology; pain and behavioral assessments; hormonal and inflammatory biomarker quantification; fertility and reproductive outcome measures; and advanced imaging (e.g., bioluminescence for luciferase-expressing xenografts). Our analytical capabilities cover molecular, cellular, and immunohistochemical assays, as well as high-throughput omics and imaging platforms. Rigorous quality control is maintained through standardized operating procedures, validated protocols, and expert veterinary oversight to ensure data reliability and reproducibility.

Partnering with Ace Therapeutics grants you access to a scientifically rigorous, fully supported in vivo endometriosis modeling platform tailored to your research objectives. Our team of experienced scientists and veterinarians ensures high-quality execution, transparent communication, and flexible study design. Accelerate your endometriosis research and therapeutic development—contact Ace Therapeutics today to discuss your project needs.